Recent Updates — DAVI
Davion Healthcare completed the acquisition of intellectual property for WoundSkan, a battery-free smart wound dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform. The total consideration is US$25 million, consisting of US$2.5 million in cash payable by February 19, 2027, and 1,730,770 new ordinary shares valued at US$13.00 per share. Shares will be issued after a 90-day deferral period ending January 20, 2027, subject to a subsequent 90-day leak-out restriction limiting sales to 10% of average daily volume. Davion Healthcare is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies.
Davion Healthcare Plc announced that ordinary shares will commence trading on the Nasdaq Global Market under ticker "DAVI" on October 22, 2026. Concurrently, the company appointed Glenn Williams as Chief Executive Officer and Jeremy North as Chief Operating Officer, effective upon the start of trading. Current CEO Jack Kaye transitions to Chairman, while Sir Eric Peacock steps down as Chairman but remains a Non-Executive Director. Davion is establishing an Operational Directorate led by Williams to drive commercialization of its flagship BreastCheck product and pursue acquisitions. The company operates in the digital healthcare sector, developing non-invasive health monitoring technologies.
Davion Healthcare PLC announced on September 9, 2026, that a £30 million senior secured bond programme issued by its UK subsidiary, Davion Healthcare Finance Ltd, was admitted to trading on the Vienna MTF. The five-year bonds, which commenced in August 2026, carry a fixed annual coupon of 10.5% and are denominated at £100,000 each with ISIN GB00BTH2SB89. This financing provides dedicated capital to support the company's acquisition strategy across medical devices, diagnostics, distribution, technology, and services. The admission does not confirm that the full principal amount has been subscribed or funded. Davion Healthcare PLC operates in the healthcare sector, focusing on the development and commercialisation of healthcare technologies and products.